Overview

Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, crossover, multicentric experimental bioequivalence study.
Phase:
Phase 1
Details
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Treatments:
Quetiapine Fumarate